Tourmaline Bio, Inc.
NASDAQ Global SelectTotal Valuation
Tourmaline Bio, Inc. carries a market capitalization of 1.23B, placing it among publicly traded companies globally. Its enterprise value stands at 172.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.23B |
| Enterprise Value | 172.69M |
Share Statistics
Tourmaline Bio, Inc. currently has 25.69M shares outstanding.
| Shares Outstanding | 25.69M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -2.27 |
| P/TBV Ratio | 1.59 |
| P/FCF Ratio | -4.77 |
| P/OCF Ratio | -4.77 |
Financial Position
Tourmaline Bio, Inc. maintains a current ratio of 24.68, meaning it holds 24.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 24.68 |
| Quick Ratio | 23.70 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -28.81 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Tourmaline Bio, Inc.'s stock has gained approximately 86.98363% over the past 52 weeks. The 50-day moving average sits at 40.68, while the 200-day moving average is 22.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | 86.98363% |
| 50-Day Moving Average | 40.68 |
| 200-Day Moving Average | 22.74 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -102.41M, while operating income came in at -102.45M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -102.45M |
| Pretax Income | -88.47M |
| Net Income | -88.47M |
| EBITDA | -102.41M |
| EBIT | -102.45M |
| Earnings Per Share (EPS) | -3.44 |
Balance Sheet
Tourmaline Bio, Inc. holds 239.23M in cash and equivalents against 145,000.00 in total debt, resulting in a net debt position of -31.42M. Total book value stands at -181.32M, with working capital of 239.01M providing operational flexibility.
| Cash & Cash Equivalents | 239.23M |
| Total Debt | 145,000.00 |
| Net Debt | -31.42M |
| Equity (Book Value) | -181.32M |
| Book Value Per Share | -7.04 |
| Working Capital | 239.01M |
Cash Flow
Tourmaline Bio, Inc. produced -86.28M in operating cash flow over the past twelve months. After subtracting -25,000.00 in capital expenditures, free cash flow totaled -86.30M - equivalent to -3.35 per share.
| Operating Cash Flow | -86.28M |
| Capital Expenditures | -25,000.00 |
| Free Cash Flow | -86.30M |
| FCF Per Share | -3.35 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.15 |
| FCF Yield | -20.95 |
Stock Splits
Tourmaline Bio, Inc.'s most recent stock split took place on October 20, 2023 with a 10:1 split ratio.
| Last Split Date | 10/20/2023 |
| Split Ratio | 10:1 |
Scores
Tourmaline Bio, Inc. posts an Altman Z-Score of 23.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 23.32 |